Innovative Technologies Excellence in technologies benefiting our pharma partners

Technologies

HalioDx has developed advanced, reliable and customizable technologies to help immunotherapies developers in rationalizing and accelerating the pace of clinical programs from early phases to registration.

This customizable solution, a sequential chromogenic multiplex IHC, in addition with whole slide digital pathology analysis, allow to assess complex TME cells phenotyping on one FFPE tumor tissue section with up-to 7 biomarkers in order to provide valuable predictive and prognostic information, as well as insights on the underlying mechanisms of therapy response and resistance.

Our expertise in immuno-oncology and our IO Biomarkers Experts and scientists ensure a fast development of your project and provide you a dedicated support during all the different steps of the development.

HalioDx has a strong expertise in complex panels development, containing up-to 7 biomarkers each, for the identification of complex cell phenotypes.

Our image and data analysts ensure a standardized quantification of cell populations and the assessment of cells clustering as well as a proximity index.

The data collected on the various panels can be combined into an Immunogram, a multimodal analysis platform, providing a 360° view of the tumor microenvironment.

Brightplex® - A customizable technology

Request your custom Brightplex® here

Immunosign® 15 and Immunosign® 21 for Clinical Research has been developed by HalioDx for Immune monitoring assay (pre and post treatment). Each signature is a custom gene panel composed of 15 and 21 predefined immune genes, respectively, applicable to most cancer types and stages for clinical investigations.

 

 

These proprietary algorithm gives you unsurpassed results in order to stratify patient into High or Low Immunosign® and explore immune orientation.

Gene expression and molecular diagnostic is in our DNA as we benefit from 20 years in successful molecular diagnostic developments on multiple platforms from QPCR to NGS.

Our NGS pipeline can fit perfectly your needs by providing molecular analysis of your samples from discovery to late stage clinical trials :

Starting from DNA

Starting from RNA

 
  • Whole Exome Sequencing (WES)
  • Targeted Sequencing
  • TCR Sequencing
 
 
  • RNA-SEQ for gene expression
  • RNA-SEQ for transcriptome sequencing
 
All solid tumor cancersAll solid tumor cancers

HalioDx provides a comprehensive offer combining information on Tumor Foreignness (TMB), Microsatellite Instability (MSI), T Cell Expansion (TCR Clonality) as well as key oncogenes mutations to better understand Immunotherapy efficacy and assess its impact on TME.

This technology provides a maximization of molecular data output from the same sample using RNA and DNA assays with a possible integration to our Immunogram, a multimodal analysis platform.



Resources on BRIGHTPLEX® and Immunosign® CR



#Brightplex®
Video

#video | Aug. 2020

2’ to learn more Series: Jacques Fieschi PhD, VP, R&D, presents the R&D department and its technologies, with a focus on Brightplex®
#Brightplex®
Poster

#poster | Jun. 2020

Unravelling the mystery of cancer-associated fibroblast (CAF) populations in the tumor microenvironment by a fully automated sequential chromogenic multiplex assay

AACR2020 Abstract # 5970

#Brightplex® | #Immunosign® CR
Video

#video | May. 2020

Webinar: Capturing the Complexity of the Tumor Microenvironment | Jérôme Galon, PhD & Jacques Fieschi, PhD
#Brightplex® | #Immunosign® CR
Video

#video | Nov. 2019

Webinar: Evaluating Biomarkers During Clinical Trials for Immunotherapies. A Case Study on the Pioneer Project
#Immunosign® CR
Poster

#poster | Nov. 2019

Poster presented at ESMO 2019 by Transgene

In the Phase Ib/II trial of TG4001, HalioDx Immunoscore®, Immunosign® and others clinical research service have been performed to assess Immune contexture of patients.

#Immunosign® CR
Video

#video | Jul. 2019

HalioDX is part of the COLOSSUS project by performing Immunoscore and help stratification of difficult to treat mCRC patients with a final objective to Improve their management and treatment
#Brightplex®
Video

#video | Jun. 2019

Webinar on Brightplex®: Combining the power of multiplexing & the ease of chromogenic IHC to assess complex immune phenotype
#Immunosign® CR
Poster

#poster | Apr. 2019

Poster presented at AACR 2019 by Lytix biopharma

A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefits in patients with advanced sarcoma

#Immunosign® CR
Poster

#poster | Apr. 2019

Poster presented at AACR 2019 by Lytix biopharma

A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma

#Brightplex®
Poster

#poster | Apr. 2019

Poster presented at AACR 2019

Validation of Brightplex®, a multiplex IHC solution for immune cell phenotyping of the tumor microenvironment

#Brightplex® | #Immunosign® CR
Brochure

#brochure | Mar. 2019

Brochure Clinical Research

HalioDx Biopharma Services

#Brightplex®
Poster

#poster | Nov. 2018

Poster presented at SITC 2018

Myeloid-derived suppressor cells (MDSC) assessment using an automated sequential chromogenic multiplex assay (Brightplex®)

#Brightplex®
Poster

#poster | Oct. 2018

Poster presented at the CRI-CIMT-EATI-AACR 2018

T cell exhaustion assessment using an automated sequential chromogenic multiplex assay (Brightplex®)

#Immunosign® CR
Poster

#poster | Jun. 2018

Poster presented at ASCO 2018 by Lytix biopharma

A Phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors

#Immunosign® CR
Poster

#poster | Nov. 2017

Poster presented at SITC 2017 by Lytix biopharma

LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the patients with advanced metastatic tumors: Results from an ongoing study

#Brightplex®
Poster

#poster | Sep. 2017

Poster presented at NSH 2017

A multiplex immunohistochemistry assay for immune cells profiling on whole FFPE tumor tissue sections

#Immunosign® CR
Poster

#poster | Jun. 2017

Poster presented at ASCO 2017 by Kite Pharma
#Immunosign® CR
Poster

#poster | Jun. 2017

Poster presented at ASCO 2017 by Lytix biopharma

LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment inducing a local and systemic effect in metastatic tumors: Results from an ongoing study

See all resources available Resources
More on our Assay Development capabilities Discover
Contact our team today, and let's talk about your project
Contact us

HalioDx newsletter subscription


Join our newsletter and be the first to get notified on new updates.


× Hide this popup.